<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851562</url>
  </required_header>
  <id_info>
    <org_study_id>FFIS/PG/2017/03</org_study_id>
    <nct_id>NCT03851562</nct_id>
  </id_info>
  <brief_title>Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy</brief_title>
  <acronym>PG-NAION</acronym>
  <official_title>Prospective, Unicentric, Randomized, Parallel, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Correction of the deficit in the perfusion pressure of the microcirculation that supplies the
      nerve by intravenous infusion of Prostaglandin E1 (PGE1) (Alprostadil), expected to improve
      visual function in patients with ischemic optic neuropathy previous non-arteritic (NOIANA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determination of visual acuity</measure>
    <time_frame>Change from baseline visual acuity at 90 days.</time_frame>
    <description>Test ETDRS (Early Treatment Diabetic Retinopathy Study)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>Day 1, day +4,day+30 , day +90.</time_frame>
    <description>Adverse Event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>Day1,day+30 , day +90.</time_frame>
    <description>Intraocular Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field</measure>
    <time_frame>Day1,day+30 , day +90.</time_frame>
    <description>Humphrey Field Analyzer (HFA),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of the layer of nerve fibers and ganglion cells in the retina</measure>
    <time_frame>Day1,day+30 , day +90.</time_frame>
    <description>Cirrus , Carl Zeiss Meditec, Dublin, California, ver: 6.0.2.81:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fundoscopic evaluation</measure>
    <time_frame>Day1,day+30 , day +90.</time_frame>
    <description>Biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic indices of the ocular arteries</measure>
    <time_frame>Day1,day+30 , day +90.</time_frame>
    <description>Doppler SIEMENS Antares™ System:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical disc area and cup / disc</measure>
    <time_frame>Day1,day+30 , day +90.</time_frame>
    <description>Cirrus , Carl Zeiss Meditec, Dublin, California, ver: 6.0.2.81:</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Alprostadil 20 micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 μg / kg patient weight up to a maximum of 60 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (physiological saline solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (physiological saline solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil 20 micrograms</intervention_name>
    <description>Intravenous infusion of PGE1 (Days 0, +1 and +2)</description>
    <arm_group_label>Alprostadil 20 micrograms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of physiological saline solution</description>
    <arm_group_label>Placebo (physiological saline solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients of both sexes between the ages of 50 and 80, both inclusive. Patients with
             the first episode of ischemic optic neuropathy previous non-arteritic / NOIANA.
             Patients with NOIANA with an evolution time from the beginning of the clinic less than
             or equal to 15 days.

          -  Potentially fertile patients should have a negative pregnancy test in serum (beta-HCG
             / human chorionic gonadotropin) or urine.

          -  Patients who offer sufficient guarantees of adherence to the protocol.

          -  Patients who give written informed consent to participate in the study.

        Exclusion Criteria:

          -  Patients with previous optic of any etiology in the affected eye.

          -  Patients with previous diagnosis or symptoms at the time of arteritis of the temporal
             artery.

          -  Patients with optic neuropathy with bilateral clinical presentation of any etiology.

          -  Patients with loss of vision due to acute hypotension in the context of a surgical
             intervention, acute hemorrhage or hemodynamic shock.

          -  Patients with severe loss of previous vision in the eye affected by ophthalmologic
             causes: severe cataract, glaucoma or intraocular pressure greater than 30 millimeters
             of mercury, severe diabetic retinopathy, macular degeneration associated with severe
             age.

          -  Patients with clinical onset in the month following major non-ocular or intraocular
             surgery

          -  Patients with abnormal elevation of CRP / C-reactive protein (&gt; 2 times the upper
             limit of normal)

          -  Patients with creatinine levels above 1.5 mg / dL.

          -  Patients on steroid treatment in the month prior to the episode.

          -  Patients under treatment with oral anticoagulants.

          -  Patients on treatment with hydroxychloroquine, ethambutol, vigabatrin at any time
             before the episode.

          -  Patients in whom the use of PGE1 (Alprostadil) is contraindicated:

          -  Patients with participation in a clinical trial in the last 6 months.

          -  Patients with inability to understand informed consent.

          -  Pregnant patients, in the postpartum period or during the active lactation period.

          -  Physically fertile patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rocio Hernandez Clares, MD</last_name>
    <phone>968 369473.</phone>
    <email>rociohclares@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Servicio de Neurología.</last_name>
      <phone>968369473</phone>
    </contact>
    <investigator>
      <last_name>Rocio Hernandez Clares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

